These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 9776134)

  • 1. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS; Fisher A; Starr MS
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
    Fisher A; Biggs CS; Eradiri O; Starr MS
    Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
    Gołembiowska K; Dziubina A
    Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
    Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain.
    Fisher A; Starr MS
    Brain Res; 2000 Jun; 868(2):268-74. PubMed ID: 10854579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K; Ferger B
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
    Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats.
    Biggs CS; Fowler LJ; Whitton PS; Starr MS
    Eur J Pharmacol; 1996 Mar; 299(1-3):83-91. PubMed ID: 8901010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.
    Neff NH; Wemlinger TA; Hadjiconstantinou M
    J Neural Transm (Vienna); 2000; 107(4):429-43. PubMed ID: 11215754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.